Dave Norwood is the founder of IP Group PLC and Oxford Science Innovation, now Oxford Science Enterprises, the largest university venture fund globally, which has brought in over 1.5 billion of investment into Oxford since its inception in 2015.

He has also founded and been a director of numerous UK technology companies including Oxford Nanopore, Proxy Imogen, Synergen, 4D Pharma, Index IT, Evolution Group and Aura Capital.

Dave is also a grandmaster in chess and has represented both England and Andorra internationally. Without Dave, much of the investment landscape of Oxford would not look how it does today.

Mark Warne was appointed as Chief Executive of the Company on 2 July 2018. Mark, who joined deepmatter^® as a Non-Executive Director in September 2015 also served as its Executive Chairman between April 2017 and July 2018. Mark is widely recognised in the UK and international life sciences sector, having spent almost ten years at IP Group Plc, a leading intellectual property commercialisation company, where he led the Healthcare team. He managed a portfolio of £330m of net assets in 2016/17 and represented IP Group on the boards of both listed and private companies. In 2018, concurrent with the integration of Touchstone Innovations into IP Group, Mark became a Partner in the Life Sciences division. He joined IP Group from pre-clinical drug discovery CRO Exelgen, where he was Managing Director. Mark spent eight years at Exelgen (formerly Tripos Discovery Research) where he also held positions in licensing and strategic affairs, project management and research. He has a PhD in Computational Chemistry, an MSc in Colloid Science and a BSc in Chemistry, all from the University of Bristol. Mark is a Chartered Chemist and member of the Royal Society of Chemistry. He serves as a Non-Executive Chair on the board of Ixico Plc and as an advisor for Angelini Ventures.

Alan Aubrey was appointed as Non-Executive Director on 27 May 2022. Alan has a successful 20-year track record in founding, developing and growing disruptive technology businesses. He co-founded Techtran Limited in 2002, which was acquired in 2005 by IP Group Plc, a company that develops world-changing science and technology businesses across life sciences, technology and cleantech. Alan was appointed IP Group’s CEO shortly after the acquisition and he went on to lead the business to become a member of the FTSE 250. Alan brings significant experience to the Group in the commercialisation of science and the creation of high growth technology businesses that address global markets.  Amongst other businesses, Alan has served on the boards of high-profile technology businesses such as Oxford Nanopore Technologies plc and Ceres Power Holdings Plc.  Alan is a Chartered Accountant and from 1995 to 2001, was a corporate finance partner in KPMG. Alan is currently Non-Executive Chairman of OxCCU Limited, an Oxford University spin-out focused on using CO₂ and renewable energy to make sustainable fuels, chemicals and plastics. He is also a Director of both Trellix Limited and Rio AI Limited, which are applying artificial intelligence to address business problems.

Bryn Roberts brings a wealth of experience in the pharmaceutical sector having spent 15 years at Roche, the Swiss multinational healthcare company. He is currently Senior Vice President and Head of Data Services at Roche Information Solutions and until recently was Global Head of Operations, Pharmaceutical Research & Early Development. As a member of the Pharmaceutical Research & Early Development Leadership Team he led innovation in disciplines such as data science and laboratory automation, including diverse applications of digital and artificial intelligence (AI) technologies.

Mirko Walter is Vice President Sales at Springer Nature, a research, educational and professional publisher. Mirko oversees a global sales team of account managers and new business specialists with a focus on workflow and data solutions. His team’s focus centres on business model and product innovation to optimise R&D workflows together with clients in areas like drug discovery and material sciences. Before joining Springer Nature, Mirko held various business development positions including at McKesson, an S&P 500 company and global leader in healthcare supply chain management solutions.